BCR and chronic myelogenous leukemia, BCR-ABL1 positive: To this end, CML cells, i.e., human K562 cells and murine myeloid 32D cell lines stably expressing either human wild-type BCR/ABL (32Dp210) or the BCR/ABL T315I mutation (32Dp210-T315I) were treated with different imatinib concentrations for 24 h, and cell viability was then assayed using the MTT assay.